CD3

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Investigational

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 20:19:17 GMT 2025` Edited by `admin` on `Tue Apr 01 20:19:17 GMT 2025`
Protein Type	RECEPTOR
Protein Sub Type	T-CELL ANTIGEN
Sequence Type	COMPLETE
Record UNII	ZLW14X2D30
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CD-3

Preferred Name

English

CD3

Common Name

English

CLUSTER OF DIFFERENTIATION 3

Common Name

English

Code System Code Type Description

FDA UNII

ZLW14X2D30

Created by admin on Tue Apr 01 20:19:17 GMT 2025 , Edited by admin on Tue Apr 01 20:19:17 GMT 2025

PRIMARY

From	To
3_24	3_65
1_27	1_76
2_27	2_76
4_16	4_52

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	3_30
N	3_70
N	4_17
N	4_53

Related Record Type Details


					6BUL1G4D60

ACTIVATOR -> TARGET

Amount:


					J43DL56H6M

FORALUMAB

INHIBITOR -> TARGET


					3QW12I37H1

WEAK AGONIST->TARGET

Amount:


					YG578HEY4V

T CELL TRANSACT, HUMAN

AGONIST -> TARGET

Amount:


					7H3Q0M9END

GBR-1342

ACTIVATOR -> TARGET


					M8FA2JKW5P

Rezetamig

ACTIVATOR -> TARGET

Comments:

Pre-clinical

Amount:


					P7MQ9ZOQ82

RESIMMUNE

CONJUGATED TOXIN->TARGET


					C416JC9CX0

IMCNYESO

ACTIVATOR -> TARGET


					JD56EJA59S

ACTIVATOR -> TARGET


					88635FW2QX

TIDUTAMAB

ACTIVATOR -> TARGET


					56FUB33G5M

ACTIVATOR -> TARGET

Amount:


					N658GY6L3E

AGONIST -> TARGET


					LK0H7J2V3C

ACTIVATOR -> TARGET


					0AHT0IC02G

LIGAND->TARGET


					HA8VPA83AE

GBR-1302

ACTIVATOR -> TARGET


					NDM64RSJ42

ACTIVATOR -> TARGET

Interaction Type:

PRECLINICAL

Amount:


					LDJ89SS0YG

ACTIVATOR -> TARGET


					PGF2HXQ0D3

ERY-974

ACTIVATOR -> TARGET


					YE8XXF1SDZ

ACTIVATOR -> TARGET

Amount:


					5W7SK85BMU

Cabotamig

ACTIVATOR -> TARGET

Amount:


					A2B6R66VSJ

LIGAND->TARGET

Comments:

CD3 delta

Amount:


					0AHT0IC02G

ACTIVATOR -> TARGET


					JGA39ICE2V

INHIBITOR -> TARGET

Amount:


					AO2W2OFG8P

LIGAND->TARGET

Amount:


					1GK8Z1OT1R

LIGAND->TARGET

Interaction Type:

IN-VITRO

Amount:


					OZ8N9U6CEH

MGD-007

ACTIVATOR -> TARGET


					M2HPV837HO

INHIBITOR -> TARGET


					4FR53SIF3A

ACTIVATOR -> TARGET

Amount:


					VT894H6T3S

ACTIVATOR -> TARGET

Amount:


					M2HPV837HO

ACTIVATOR -> TARGET


					H57D6SR4FE

ACTIVATOR -> TARGET

Interaction Type:

PRECLINICAL

Amount:


					I5HF2X04PB

ACTIVATOR -> TARGET

Amount:


					UGA95385P3

AFM-11

LIGAND->TARGET


					P9I9Z3MF7Z

ACTIVATOR -> TARGET

Amount:


					KX8KZX98PB

ACTIVATOR -> TARGET

Amount:


					5ENX424FNF

ACTIVATOR -> TARGET


					3NCP89Y74H

Obertamig

ACTIVATOR -> TARGET

Amount:


					8RV18E4A94

LIGAND->TARGET

Amount:


					4W3KFI3TN3

ACTIVATOR -> TARGET

Amount:


					AG8ULI6K9U

DAFSOLIMAB SETARITOX

LIGAND->TARGET

Amount:


					L93WSG9AAU

NG-641

ACTIVATOR -> TARGET

Interaction Type:

PRECLINICAL

Amount:


					4FR53SIF3A

ACTIVATOR -> TARGET


					L5L45YGP1O

ACTIVATOR -> TARGET

Amount:


					30WLL6DR9O

ACTIVATOR -> TARGET

Amount:


					GLR3JG8TZU

ACTIVATOR -> TARGET

Amount:


					CO86AOP337

Etentamig

ACTIVATOR -> TARGET

Amount:


					L0HR9A577V

ACTIVATOR -> TARGET

Amount:


					HOG226RYH1

ACTIVATOR -> TARGET


					P5TLS56PWW

Cizutamig

ACTIVATOR -> TARGET

Interaction Type:

PRECLINICAL

Amount:


					2X6WP45UD6

LIGAND->TARGET

Interaction Type:

PRECLINICAL

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL